Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 46, Issue 8

Issues

Evaluation of the DCA Vantage analyzer for HbA1c assay

Jean Szymezak
  • 1Laboratory of Pediatric Biology and Research, American Memorial Hospital, University Hospital of Reims, Reims, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Nathalie Leroy
  • 2Laboratory of Pediatric Biology and Research, American Memorial Hospital, University Hospital of Reims, Reims, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Emmanuelle Lavalard
  • 3Laboratory of Pediatric Biology and Research, American Memorial Hospital, University Hospital of Reims, Reims, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Philippe Gillery
  • 4Laboratory of Pediatric Biology and Research, American Memorial Hospital, University Hospital of Reims, Reims, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2008-06-27 | DOI: https://doi.org/10.1515/CCLM.2008.228

Abstract

Background: Measurement of HbA1c is key in monitoring diabetic patients in both laboratories and clinical units, where HbA1c results are used as part of patient education.

Methods: We have evaluated the DCA Vantage®, a new device for immunological assay of HbA1c. HbA1c results obtained were evaluated in terms of precision, linearity, specificity and practicability, and were compared with results obtained by a Variant II® HPLC method.

Results: The method exhibited intra- and inter-assay coefficients of variation lower than 2.6% and 4.0%, respectively, and good correlation with the comparison HPLC method (r2=0.9776). No interference was noted in the presence of labile HbA1c or carbamylated hemoglobin. The new device exhibited improved practicability characteristics and allowed better sample identification, better management of quality control routines and greater connectivity possibilities compared to the previous DCA 2000® analyzer.

Conclusions: This new analyzer exhibited analytical and practical characteristics very suitable for HbA1c assay for laboratory or point-of-care use according to good laboratory practice.

Clin Chem Lab Med 2008;46:1195–8.

Keywords: diabetes mellitus; evaluation; HbA1c; immunoassay; patient outcome; point-of-care testing

About the article

Corresponding author: Philippe Gillery, MD, PhD, Laboratory of Pediatric Biology and Research, American Memorial Hospital, CHU Reims, 47 rue Cognacq-Jay, 51092 Reims cedex, France Phone: +33-3-26787563, Fax: +33-3-26783882,


Received: 2008-02-21

Accepted: 2008-04-11

Published Online: 2008-06-27

Published in Print: 2008-08-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 46, Issue 8, Pages 1195–1198, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2008.228.

Export Citation

©2008 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Irina L. Dubach, Emanuel R. Christ, and Peter Diem
Primary Care Diabetes, 2019
[2]
Luke M. Weinel, Matthew J. Summers, Mark E. Finnis, Alexis Poole, Palash Kar, Marianne J. Chapman, Adam M. Deane, and Yasmine Ali Abdelhamid
Australian Critical Care, 2018
[3]
[4]
Anne F. Goemans, Susanna J. Spence, and Ian K. Ramsey
Veterinary Clinical Pathology, 2017, Volume 46, Number 2, Page 227
[5]
Jamie R. Wood, Brett M. Kaminski, Craig Kollman, Roy W. Beck, Callyn A. Hall, Jason P. Yun, Eda Cengiz, Michael J. Haller, Krishna Hassan, Georgeanna J. Klingensmith, and William V. Tamborlane
Journal of Diabetes Science and Technology, 2012, Volume 6, Number 2, Page 380
[6]
Erna Lenters-Westra and Robbert J. Slingerland
Journal of Diabetes Science and Technology, 2009, Volume 3, Number 3, Page 418
[7]
Sujaytha Paknikar, Rohan Sarmah, Losika Sivaganeshan, Adam Welke, Al Rizzo, Kirk Larson, and Marc Rendell
Journal of Diabetes Science and Technology, 2016, Volume 10, Number 6, Page 1308
[9]
DH Zhang, QN Yuan, PM Zabala, F Zhang, L Ngo, and IB Darby
Australian Dental Journal, 2015, Volume 60, Number 4, Page 455
[10]
Jenise C. Wong, Aaron B. Neinstein, Matthew Spindler, and Saleh Adi
Diabetes Technology & Therapeutics, 2015, Volume 17, Number 8, Page 555
[11]
Lara A. Motta, Mark D.S. Shephard, Heather J. Halls, Glennis Barnes, and John Senior
Point of Care: The Journal of Near-Patient Testing & Technology, 2015, Volume 14, Number 1, Page 25
[13]
M. Martin, N. Leroy, V. Sulmont, and P. Gillery
Diabetes & Metabolism, 2010, Volume 36, Number 2, Page 158
[14]
Jean Szymezak, Emmanuelle Lavalard, Michèle Martin, Nathalie Leroy, and Philippe Gillery
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 5

Comments (0)

Please log in or register to comment.
Log in